Skip to main content
. Author manuscript; available in PMC: 2013 May 21.
Published in final edited form as: Cancer Res. 2010 Oct 5;70(20):7776–7787. doi: 10.1158/0008-5472.CAN-10-2229

Figure 7.

Figure 7

The SRIS predicts good outcome within the Her2 and basal subtypes. Kaplan-Meier analysis within the SRIS-low (blue) and SRIS-high (red) groups for each of the molecular (A) or immunohistochemical (B) subtypes. The number of patients within each subtype is shown. HR, hazards ratio. C, ShcA-deficient mammary epithelial cells are debilitated in their ability to progress from hyperplasia. Loss of ShcA signaling relieves immunosuppression in early hyperplastic mammary glands, resulting in the activation of an antitumorigenic Th1/CTL response. Progressively growing lesions, however, polarize the immune response to favor Th2-mediated immunity, which establishes a chronic inflammatory state to favor transition to carcinoma.